Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefaliv
- Development stage
- Discontinued
- Lead developer
- Ache Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Cefaliv** is an oral fixed-dose antimigraine tablet marketed by Aché for acute headache attacks, including migraine. Each tablet contains dihydroergotamine mesylate 1 mg, dipyrone monohydrate 350 mg, and caffeine 100 mg. Dihydroergotamine is an ergot-derived antimigraine agent with agonist activity at serotonin 5-HT1B and 5-HT1D receptors; dipyrone provides non-opioid analgesic and antipyretic activity; and caffeine is an analgesic adjuvant that antagonizes adenosine receptors. ([bula.ache.com.br](https://bula.ache.com.br/produto/sob-prescricao/cefaliv?sitejourney=true))
- Brand names
- Cefaliv
- Other names
- caffeine + dihydroergotamine mesylate + dipyrone monohydrate
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)HTR1F (Serotonin 5-HT1F receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR3A (5-hydroxytryptamine receptor 3A)ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)ADRA1A (α1A)ADRA1B (α1B)ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)
Beyond the preview
Go deeper on Cefaliv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cefaliv.